US Biomax - Prostate Cancer Tissue Array With Matched Normal Adjacent Tissue And Metastatic Bones, With TNM, Gleason Scores, PSA Level And Survival Data, 40 Cases/95 Cores, Replacing PR952

Prostate Sub-types (41)

Paraffin Embedded Tissue Array Types [view all]

Human

PR953

Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases/95 cores, replacing PR952

Unstained: $345.00

H&E (PR953s*): $345.00

Microarray Panel:	Prostate adenocarcinoma tissue microarray, duplicated cores, 36 cancer and 8 of which has matched normal adjacent tissue and 3 cases of metastasis in bones and 1 in abdominal wall,with follow-up data
Cores:	95
Cases:	40
Layout:	12 cols × 8 rows
Core Diameter:	1.5 mm
Thickness:	5 µm
Quality Control:	Anti-Actin confirmed
Applications:	Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.
Notes:	1. Some slides are covered by a thin layer of paraffin to prevent oxidization and decay, thus are recommended be baked at 56-60°C up to 2 hours until the paraffin melt before doing regular IHC or ISH procedures. 2. For slides not coated with paraffin (those tissue cores can be easily seen on the glass), there is no need to bake, can be directly put into xylene for de-paraffin procedure.

*Tissue Microarray Slide Types:

Unstained: unstained paraffin tissue microarray slide.
Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
H & E: Hematoxylin and Eosin stained tissue microarray slide.

Microarray Panel Display

Slide Label: US Biomax, Inc. Tissue Array

	1	2	3	4	5	6	7	8	9	10	11	12
A
B
C
D
E
F
G
H

Legend:

Abd - Abdominal wall, Bon - Bone, Car - Carbon, Pro - Prostate

- Carbon, - Malignant tumor (stage II), - Malignant tumor (stage III), - Malignant tumor (stage IV), - Metastasis, - NAT

Specification Sheet

Pos	No.	Sex	Age	Organ	Pathology diagnosis	Stage	Gleason Score	TNM	Months	Type †
A1, A2	1	M	68	Prostate	Adenocarcinoma	III	9	T3bN0M0	.	Malignant
A3, A4	2	M	64	Prostate	Adenocarcinoma	II	7	T2cN0M0	.	Malignant
A5, A6	3	M	71	Prostate	Adenocarcinoma	III	9	T3bN0M0	.	Malignant
A7, A8	4	M	64	Prostate	Adenocarcinoma	III	10	T3aN0M0	.	Malignant
A9, A10	5	M	59	Prostate	Adenocarcinoma	III	9	T3bN0M0	.	Malignant
A11, A12	6	M	65	Prostate	Adenocarcinoma	IV	8	T4N0M0	.	Malignant
B1, B2	7	M	73	Prostate	Adenocarcinoma	II	7	T2cN0M0	.	Malignant
B3, B4	8	M	69	Prostate	Adenocarcinoma	II	7	T2cN0M1	.	Malignant
B5, B6	9	M	62	Prostate	Adenocarcinoma	II	7	T2cN0M1	.	Malignant
B7, B8	10	M	66	Prostate	Adenocarcinoma	III	9	T3bN0M0	.	Malignant
B9, B10	11	M	60	Prostate	Adenocarcinoma	III	9	T3bN0M0	.	Malignant
B11, B12	12	M	70	Prostate	Adenocarcinoma	IV	7	T4N0M0	.	Malignant
C1, C2	13	M	65	Prostate	Adenocarcinoma	III	9	T3bN0M1	.	Malignant
C3, C4	14	M	67	Prostate	Adenocarcinoma	IV	9	T3bN1M0	.	Malignant
C5, C6	15	M	69	Prostate	Adenocarcinoma	III	7	T3bN0M0	.	Malignant
C7, C8	16	M	69	Prostate	Adenocarcinoma	III	7	T3aN0M1	.	Malignant
C9, C10	17	M	70	Prostate	Adenocarcinoma	III	7	T3aN0M1	.	Malignant
C11, C12	18	M	58	Prostate	Adenocarcinoma	III	9	T3bN0M0	.	Malignant
D1, D2	19	M	71	Prostate	Adenocarcinoma	II	7	T2cN0M0	.	Malignant
D3, D4	20	M	70	Prostate	Adenocarcinoma	III	7	T3bN0M0	.	Malignant
D5, D6	21	M	59	Prostate	Adenocarcinoma	II	6	T2bN0M0	.	Malignant
D7, D8	22	M	63	Prostate	Adenocarcinoma	III	9	T3bN0M0	.	Malignant
D9, D10	23	M	72	Prostate	Adenocarcinoma	III	9	T3bN0M0	.	Malignant
D11, D12	24	M	66	Prostate	Adenocarcinoma	III	8	T3bN0M0	.	Malignant
E1, E2	25	M	70	Prostate	Adenocarcinoma	II	7	T2cN0M1	.	Malignant
E3, E4	26	M	68	Prostate	Adenocarcinoma	III	8	T3bN0M0	.	Malignant
E5, E6	27	M	63	Prostate	Adenocarcinoma	III	10	T3bN0M1	.	Malignant
E7, E8	28	M	57	Prostate	Adenocarcinoma	III	7	T3bN0M0	.	Malignant
E9, E10	29	M	72	Prostate	Adenocarcinoma	III	8	T2cN0M0	.	Malignant
E11, E12	30	M	70	Prostate	Adenocarcinoma	III	8	T3bN0M0	.	Malignant
F1, F2	31	M	75	Prostate	Adenocarcinoma	III	9	T3bN0M0	.	Malignant
F3, F4	32	M	62	Prostate	Adenocarcinoma	III	9	T3bN0M0	.	Malignant
F5, F6	33	M	63	Prostate	Adenocarcinoma	III	9	T3bN0M0	.	Malignant
F7, F8	34	M	53	Prostate	Adenocarcinoma	III	9	T3bN0M0	.	Malignant
F9, F10	35	M	63	Prostate	Adenocarcinoma	III	8	T3bN0M0	.	Malignant
F11, F12	36	M	44	Prostate	Adenocarcinoma	III	7	T3bN0M1	.	Malignant
G1, G2	37	M	65	Abdominal wall	Metastatic adenocarcinoma from prostate	IV	.	M1	36	Metastasis
G3, G4	38	M	61	Bone	Metastatic adenocarcinoma from prostate	IV	.	M1	32	Metastasis
G5, G6	39	M	69	Bone	Metastatic adenocarcinoma from prostate	IV	.	M1	34	Metastasis
G7, G8	40	M	59	Bone	Metastatic adenocarcinoma from prostate	IV	.	M1	0	Metastasis
G9, G10	41	M	69	Prostate	Normal (match of #8)	.	.	.	.	NAT
G11, G12	42	M	62	Prostate	Normal (match of #9)	.	.	.	.	NAT
H1, H2	43	M	65	Prostate	Normal (match of #13)	.	.	.	.	NAT
H3, H4	44	M	69	Prostate	Normal (match of #16)	.	.	.	.	NAT
H5, H6	45	M	70	Prostate	Normal (match of #17)	.	.	.	.	NAT
H7, H8	46	M	70	Prostate	Normal (match of #25)	.	.	.	.	NAT
H9, H10	47	M	63	Prostate	Normal (match of #27)	.	.	.	.	NAT
H11	48	M	44	Prostate	Normal (match of #36)	.	.	.	.	NAT

* Month, interval between primary and metastatic cancer
** TNM and stage, AJCC Cancer Staging Manual (6th Edition)， pTNM, pathological TNM

† For precise diagnosis, refer to pathology description.

Supplementary Data

Pos	No.	PSA (ng/ml)	Residual tumor	Follow-up months	Follow-up result	Cause of death	Remark
A1, A2	1	.	.	.	.	.	.
A3, A4	2	30	R0	60	alive	.	.
A5, A6	3	60.4	R1	55	alive	.	.
A7, A8	4	7.4	R1	47	alive	.	.
A9, A10	5	9.8	R1	44	alive	.	.
A11, A12	6	34.9	R1	43	alive	.	.
B1, B2	7	48.1	R1	42	alive	.	.
B3, B4	8	10.6	R0	42	alive	.	.
B5, B6	9	37.3	R1	39	alive	.	.
B7, B8	10	1.2	R1	39	alive	.	.
B9, B10	11	40	R1	39	alive	.	.
B11, B12	12	7	R1	37	alive	.	.
C1, C2	13	17.5	R1	23	dead	cancer	.
C3, C4	14	13.1	R1	34	alive	.	.
C5, C6	15	1.1	R1	33	alive	.	.
C7, C8	16	17.6	R1	27	alive	.	.
C9, C10	17	9	R1	26	alive	.	.
C11, C12	18	5.8	R0	26	alive	.	.
D1, D2	19	31.4	R1	24	alive	.	.
D3, D4	20	14.4	R1	19	alive	.	.
D5, D6	21	18.3	R0	18	alive	.	.
D7, D8	22	16.6	R1	17	alive	.	.
D9, D10	23	.	R1	16	alive	.	.
D11, D12	24	10.8	R1	17	dead	cancer	.
E1, E2	25	.	R0	15	alive	.	.
E3, E4	26	26.9	R1	15	alive	.	.
E5, E6	27	.	R1	15	alive	.	.
E7, E8	28	25	R1	15	alive	.	.
E9, E10	29	16.8	R1	15	alive	.	.
E11, E12	30	0.5	R1	15	alive	.	.
F1, F2	31	98	R1	15	alive	.	.
F3, F4	32	.	R1	15	alive	.	.
F5, F6	33	91	R1	14	alive	.	.
F7, F8	34	161	R1	17	dead	cancer	.
F9, F10	35	13	R1	13	alive	.	.
F11, F12	36	.	R1	11	alive	.	.
G1, G2	37	.	.	.	.	.	.
G3, G4	38	.	.	.	.	.	.
G5, G6	39	.	.	.	.	.	.
G7, G8	40	.	.	.	.	.	.
G9, G10	41	.	.	.	.	.	.
G11, G12	42	.	.	.	.	.	.
H1, H2	43	.	.	.	.	.	.
H3, H4	44	.	.	.	.	.	.
H5, H6	45	.	.	.	.	.	.
H7, H8	46	.	.	.	.	.	.
H9, H10	47	.	.	.	.	.	.
H11	48	.	.	.	.	.	.

TNM grading:

T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis

Find overlapping cases with this tissue array:

Paraffin Embedded Tissue Array Types [view all]

Human

Mouse (15)

Rat (9)